Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.

ABSTRACT:

Background

The efficacy and safety of apremilast were assessed in patients with psoriatic arthritis (PsA) in three phase III clinical trials with similar designs (PALACE 1, 2, and 3).

Methods

Following a 24-week, randomized (1:1:1 to apremilast 30 mg twice daily, 20 mg twice daily, or placebo), double-blind phase and a 28-week blinded active treatment phase, patients could receive apremilast in open-label extension studies for an additional 4 years. Eligible adult patients had active PsA for ≥ 6 months and three or more swollen joints and three or more tender joints despite prior treatment with disease-modifying anti-rheumatic drugs.

Results

A total of 1493 randomized patients received one or more doses of study medication (placebo: n = 496; apremilast 30 mg twice dai

SUBMITTER: Kavanaugh A 

PROVIDER: S-EPMC6509758 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature